Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- J&J vs. Merck and Schering: Who Is Most Desperate in This Bizarre Love Triangle?
- Nobody wants to say anything about the great Remicade tug of war that has broken out between Johnson & Johnson and the soon-to-be-merged Merck and Schering-Plough. A look at the Q1 2009 numbers suggest that each member of this trio has their own reasons to be quietly...
- Blog posts 2009-04-24
Additional Resources
- FDA Approves Remicade(R) Regimen as First Line Therapy in Patients With Moderate to Severe Rheumatoid Arthritis
- Centocor, Inc. announced today that the U.S. Food and Drug Administration FDA has approved an expanded label for REMICADE® infliximab in combination with methotrexate REMICADE regimen, as a first line regimen to treat patients with moderate to severe rheumatoid arthritis RA. The expanded label eliminates the requirement that patients...
- Research articles 2004-09-30
- Study of Claims Data Finds REMICADE Dosing Remains Stable with Maintenance Therapy over Two Year Period
- ORLANDO, Fla. -- Headline of release should read: Study of Claims Data Finds REMICADE Dosing Remains Stable with Maintenance Therapy over Two Year Period sted Study of Claims Data Finds REMICADE Dosing Remains Stable with Maintenace Therapy over Two Year Period. The corrected release reads: STUDY OF CLAIMS...
- Research articles 2004-11-02
- FDA approves Centocor’s Remicade for psoriasis
- Centocor Inc., of Horsham, said today that U.S. regulators have approved its rheumatoid arthritis drug, Remicade, to treat the dermatological condition, psoriasis. The biotechnology subsidiary of Johnson & Johnson said eight out of 10 patients treated with Remicade, known by the chemical name infliximab, had a 75 percent improvement in...
- Research articles 2006-09-27
- REMICADE Granted Priority Review by U.S. Food and Drug Administration for Treatment of Ulcerative Colitis; First Biologic to Show Efficacy in Phase III Trials for Ulcerative Colitis
- HORSHAM, Pa. -- Centocor, Inc. announced today that the supplemental biologics license application sBLA for REMICADER infliximab for the treatment of ulcerative colitis UC has been designated for priority review by the U.S. Food and Drug Administration FDA. In Phase III clinical trials, REMICADE was studied as a monotherapy to...
- Research articles 2005-05-31
- FDA Approves Remicade(R) as First and Only Biologic to Treat Ulcerative Colitis
- Centocor, Inc. announced today that REMICADE® infliximab has been approved by the U.S. Food and Drug Administration FDA for the treatment of ulcerative colitis UC, making REMICADE the first and only biologic approved for UC, a chronic inflammatory bowel disease IBD.
- Research articles 2005-09-16
- FDA Approves REMICADE for Patients with Ankylosing Spondylitis, a Debilitating Inflammatory Condition of the Spine; Label Also Updated to Include Important Safety Information
- MALVERN, Pa. -- Centocor, Inc. announced today that the U.S. Food and Drug Administration FDA has approved REMICADER infliximab for the treatment of ankylosing spondylitis AS. REMICADE is now indicated for reducing signs and symptoms in active AS, a painful, progressive inflammatory condition of the spine that can result in...
- Research articles 2004-12-20
- Psoriasis Group Hails FDA Approval of Remicade for Psoriatic Arthritis
- KENSINGTON, Md., May 17 /U.S. Newswire/ -- "Psoriasis Cure Now," a patient advocacy group, responded today to news that the U.S. Food and Drug Administration FDA has approved Remicade infliximab to reduce the signs and symptoms of active artKENSINGTON, Md., May 17 /U.S. Newswire/ -- "Psoriasis Cure Now," a patient...
- Research articles 2005-05-17
- Arthritis Drug Remicade Swells Patient Costs, Medicare Official Says.
- By Marsha Austin, The Denver Post Knight Ridder/Tribune Business News Jul. 22--John Pierson, who has rheumatoid arthritis, says Remicade gave him back his life. "There have been times when I literally could not move," said the 59-year-old teacher from Denver,...
- Research articles 2002-07-22
- New Medicare Coding Announced for Infusion Services; Fulfills CMS Commitment to Appropriate Reimbursement; REMICADE Receives Access to Cancer Code
- MALVERN, Pa. -- Centocor said that the new Medicare physician reimbursement policy announced yesterday by the Centers for Medicare and Medicaid Services CMS will facilitate increased patient access to REMICADE in a health care provider's office. REMICADE R infliximab is Centocor's treatment for rheumatoid arthritis RA and Crohn's disease. ...
- Research articles 2004-11-04
- REMICADE(R) Shows Efficacy in Treatment of Ulcerative Colitis in Phase III Clinical Trials
- Results from two Phase III trials presented today at Digestive Disease Week® 2005 reveal that, among patients with moderate to severe, active ulcerative colitis UC who experienced an inadequate response to conventional therapy, nearly 70 percent of patients at week 8 demonstrated significant improvement in their symptoms with REMICADE® infliximab...
- Research articles 2005-05-16
- FDA OKs Remicade for use in kids with Crohn’s
- Centocor Inc., of Horsham, said today U.S. regulators have approved its Remicade rheumatoid arthritis drug to treat Crohn's disease in children. The Food and Drug Administration said in a statement on the agency's Web site that there have been no satisfactory treatments for children with moderate to severe Crohn's...
- Research articles 2006-05-19
- Centocor says study bolsters Remicade as psoriasis treatment
- Centocor Inc. announced today results of a patient study that the Horsham company said bolsters earlier clinical trial findings that its drug Remicade is effective in treating psoriasis, a chronic inflammatory skin condition. The study, involving 1,462 patients, found that three-quarters taking Remicade for severe psoriasis achieved a 75...
- Research articles 2007-02-02
- New risks force Remicade trial to stop
- What risks do sponsors face when studying a proven therapy for a new indication? In Centocor's case, it is the discovery in new trial data that its top FDA-approved product, Remicade infliximab, has a higher incidence of mortality and hospitalization in patients the drug was intended to help. Remicade is...
- Research articles 2001-12-01
- Brochure to Doctors Highlights Studies on the Safety of J&J's Remicade
- To: LABOR EDITORSContact: Edgar Sandoval, +1-212-539-2940 or +1-646-673-4102, or Matt Nerzig, +1-212-539-2882, both of SEIU Local 32BJ PHILADELPHIA, May 7 /PRNewswire-USNewswire/ -- A brochure mailed today to more than 400 rheumatologists in the Northeast highlights scientific studies that raise questions about the safety and effectiveness of the prescription drug Remicade...
- Research articles 2007-05-07
- Tanabe Seiyaku, Centocor Revise Licensing Agreement on Remicade, Anti
- Tanabe Seiyaku (TSE: 4508) has announced that it has signed an addendum to its licensing agreement with Centocor of Pennsylvania for Remicade, an anti-TNF-alpha monoclonal antibody preparation developed by Centocor. Currently, Tanabe Seiyaku is marketing Remicade for two indications, Crohn's disease and rheumatoid arthritis, and has filed...
- Research articles 2005-02-01
- REMICADE® Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response in the Treatment of Moderate to Severe Psoriasis; Findings from Two Phase 3 Studies Show High-Level, Sustained Response with Maintenance Therapy
- SAN FRANCISCO -- Phase 3 data show treatment with REMICADER infliximab resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the EXPRESS II trial, a placebo-controlled, dose-ranging study of REMICADE 3 mg/kg and 5 mg/kg, showed that every eight week maintenance...
- Research articles 2006-03-06
- Remicade OK
- The FDA has approved Remicade as a treatment for rheumatoid arthritis patients who have had inadequate response to methotrexate alone. Centocor Inc. and Ortho-McNeil Pharmaceutical Inc. (both Johnson & Johnson units) are copromoting Remicade.
- Research articles 1999-12-06
- Trial to offer insights on Remicade
- NEW ORLEANS -- Centocor Inc. and Schering-Plough Corp. have debuted the first trial comparing biologic therapy with conventional therapy in patients with Crohn's disease. The study is comparing the efficacy of Remicade with that of azathioprine alone and in combination with the former. "We look forward to receiving the...
- Research articles 2004-06-07
- FDA Advisory Committee Recommends Approval Of Remicade(R) With Methotrexate For Reduction Of Joint Damage In Patients With Rheumatoid Arthritis
- Centocor, Inc. said today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration FDA voted unanimously to recommend approval of REMICADER infliximab with methotrexate for reduction of structural damage in patients with rheumatoid arthritis. REMICADE with methotrexate is currently approved for treatment of rheumatoid arthritis in...
- Research articles 1970-01-01
- << Previous
- page 1 of 1
- Next >>
